Q-omics provides the consensus-scored BPIFC profile across patient tissues and cancer cell-line models. BPIFC expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, BPIFC is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, BPIFC RNA expression shows 8,965 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight KIRC, and ESCA as cancer lineages where BPIFC shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BPIFC — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BPIFC survival associations across molecular data types. BPIFC RNA expression shows survival associations in the most cancer types (25), followed by mutation status (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BPIFC RNA expression–survival associations across cancer types. High BPIFC expression shows unfavorable associations in KIRC, ACC, BLCA and COAD, but favorable associations in READ and ESCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for BPIFC RNA expression.
This table summarizes BPIFC tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for BPIFC. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BPIFC shows lower tumor expression in KIRC, KICH, THCA and COAD and higher tumor expression in LUSC and LUAD. The KIRC box plot shows higher BPIFC RNA expression in normal versus tumor tissue (log2 FC = −0.042, t-test p < 0.001).
This table shows molecular features associated with BPIFC in patient tissues and cancer cell lines. In patient samples, BPIFC shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set. In cancer cell lines, BPIFC RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
